Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Myotrophin expanded access program initiated

Aug. 16, 1996

Genetic insights into MS reported

Aug. 16, 1996

Pfizer investigates enantiomeric profiles of citalopram, fluoxetine

Aug. 16, 1996

Lamotrigine, valproate tested in mood disorders

Aug. 16, 1996

Meiji Seika claims bicyclic thiazoles for CNS disorders

Aug. 16, 1996

Allelix describes D4 antagonists for schizophrenia

Aug. 16, 1996

BTS-73947: new D1/D5 antagonist from Knoll

Aug. 16, 1996

Roche profiles pharmacokinetics, pharmacodynamics of new benzodiazepine

Aug. 16, 1996

first clinical study results reported for Ro-48-6791

Aug. 16, 1996

LY-23728, 5-HT2B antagonist reported by Lilly

Aug. 16, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...